<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03610646</url>
  </required_header>
  <id_info>
    <org_study_id>MYL-1701P-3001</org_study_id>
    <nct_id>NCT03610646</nct_id>
  </id_info>
  <brief_title>Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema</brief_title>
  <official_title>A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mylan Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Momenta Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mylan Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Three hundred and twenty-four (324) eligible adult subjects with diabetes mellitus with&#xD;
      central DME involvement will be randomized 1:1 to intravitreal treatment with MYL-1701P or&#xD;
      Eylea®.&#xD;
&#xD;
      The primary endpoint will be mean change from baseline in BCVA as assessed by ETDRS letters.&#xD;
      Pharmacokinetics (PK) and immunogenicity will be evaluated in the subjects participating in&#xD;
      the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Three hundred and twenty-four (324) eligible adult subjects with diabetes mellitus with&#xD;
      central DME involvement will be randomized 1:1 to intravitreal treatment with MYL-1701P or&#xD;
      Eylea®. Subjects will receive the assigned treatment until Week 48.&#xD;
&#xD;
      All subjects will return to clinic every 4 weeks to assess safety, efficacy and to guide&#xD;
      treatment. There will be additional visits during the study as specified in the study&#xD;
      schedule for safety and pharmacokinetic evaluation.&#xD;
&#xD;
      Pharmacokinetics (PK) and Immunogenicity will be assessed in the subjects participating in&#xD;
      the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 23, 2018</start_date>
  <completion_date type="Actual">September 10, 2021</completion_date>
  <primary_completion_date type="Actual">November 10, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants are assigned to either MYL-1701P or Eylea groups in parallel for the duration of the study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Masked study drug kits will be supplied to sites as necessary during the study. The outside label of the box will not reveal the identity of the product inside (whether it is Eylea or MYL-1701P) and will be assigned in a masked fashion through the IRT system. An un-masked team will identified at site, to be responsible for preparation and administration of the study drug.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The mean change from baseline in BCVA at week 8</measure>
    <time_frame>From baseline to week 8</time_frame>
    <description>The mean change from baseline in BCVA as assessed by ETDRS letters at week 8</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The mean change from baseline in CRT</measure>
    <time_frame>From baseline to week 52</time_frame>
    <description>The mean change from baseline in CRT as determined by SD-OCT over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean change in BCVA</measure>
    <time_frame>From baseline to week 52</time_frame>
    <description>The mean change in BCVA over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who gained ≥15 letters from Baseline in BCVA</measure>
    <time_frame>From baseline to week 52</time_frame>
    <description>Proportion of subjects who gained ≥15 letters from baseline in BCVA, assessed in change from baseline in ETDRS letters over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of administrations of study drug required</measure>
    <time_frame>From baseline to week 52</time_frame>
    <description>Number of administrations of study drug required</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment emergent adverse events (Safety and tolerability)</measure>
    <time_frame>From baseline to week 52</time_frame>
    <description>Incidence of treatment emergent adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects testing positive for Anti-Drug Antibodies (ADA) (Immunogenicity)</measure>
    <time_frame>From baseline to week 52</time_frame>
    <description>Proportion of subjects testing positive for Anti-Drug Antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of aflibercept in blood (Pharmacokinetics)</measure>
    <time_frame>From baseline to week 52</time_frame>
    <description>Concentration of aflibercept in blood (Pharmacokinetics)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">355</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>MYL-1701P</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MYL-1701P</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eylea</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eylea</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MYL-1701P</intervention_name>
    <description>Subjects will receive intravitreal injections of MYL-1701P throughout the 52-week treatment period, with the last dose at 48 weeks.&#xD;
The additional doses may be administered in accordance with the protocol.</description>
    <arm_group_label>MYL-1701P</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eylea</intervention_name>
    <description>Subjects will receive intravitreal injections of Eylea throughout the 52-week treatment period, with the last dose at 48 weeks.&#xD;
The additional doses may be administered in accordance with the protocol.</description>
    <arm_group_label>Eylea</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects age ≥ 18 years.&#xD;
&#xD;
          2. Subjects have type 1 or type 2 diabetes mellitus who present with central DME&#xD;
             involvement in the study eye.&#xD;
&#xD;
          3. The cause of decreased vision in the study eye has been attributed primarily to DME by&#xD;
             the Investigator.&#xD;
&#xD;
          4. Subject is able to understand and voluntarily provide written informed consent to&#xD;
             participate in the study.&#xD;
&#xD;
          5. If female of child bearing potential, the subject must have a negative serum pregnancy&#xD;
             test at the Screening visit and a negative urine pregnancy test at baseline visit, and&#xD;
             should not be nursing or planning a pregnancy.&#xD;
&#xD;
          6. If female, subject must be:&#xD;
&#xD;
               1. Surgically sterilized via hysterectomy, bilateral oophorectomy, or bilateral&#xD;
                  tubal ligation; or&#xD;
&#xD;
               2. Of childbearing potential and practicing an acceptable form of birth control&#xD;
                  (defined as the use of an intrauterine device; a barrier method, like condom,&#xD;
                  with spermicide; any form of hormonal contraceptives; or abstinence from sexual&#xD;
                  intercourse) starting 60 days prior to dosing and continuing at least 90 days&#xD;
                  following the last treatment.&#xD;
&#xD;
               3. Of non-childbearing potential (i.e., postmenopausal for at least 1 year).&#xD;
&#xD;
          7. If male, subject must be surgically or biologically sterile. If not sterile, the&#xD;
             subject must agree to use an acceptable form of birth control with sexual partner (as&#xD;
             described in inclusion criteria #6b of protocol) or abstain from sexual relations&#xD;
             during the study period and up to 90 days following the last treatment dose.&#xD;
&#xD;
          8. Subject is willing to comply with the study duration, study visits and study related&#xD;
             procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with known hypersensitivity to aflibercept or any of the excipients&#xD;
&#xD;
          2. Subjects with current or planned use of systemic medications known to be toxic to the&#xD;
             lens, retina or optic nerve, including deferoxamine, chloroquine/hydroxychloroquine,&#xD;
             tamoxifen, phenothiazines and ethambutol&#xD;
&#xD;
          3. Subjects with uncontrolled hypertension defined as systolic blood pressure &gt;160mm Hg&#xD;
             or diastolic blood pressure &gt; 95 mm of Hg.&#xD;
&#xD;
          4. Subjects with a history of cerebrovascular accident or myocardial infarction within 6&#xD;
             months of randomization.&#xD;
&#xD;
          5. Subjects with history of use of intraocular corticosteroids anytime in the past or&#xD;
             periocular (subconjunctival, intra-scleral, sub-tenon or retrobulbar) corticosteroids&#xD;
             within 4 months of randomization&#xD;
&#xD;
          6. Subjects who have only one functional eye, even if the eye met all other study&#xD;
             requirements, or who have an ocular condition on the fellow eye with a poorer&#xD;
             prognosis than the study eye.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95841</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33880</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Shawnee Mission</city>
        <state>Kansas</state>
        <zip>66204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Ladson</city>
        <state>South Carolina</state>
        <zip>29456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Abilene</city>
        <state>Texas</state>
        <zip>79606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Praha 10</city>
        <state>Vinohrady</state>
        <zip>10034</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Hradec Králové</city>
        <zip>50005</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Olomouc</city>
        <zip>77900</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Pardubice</city>
        <zip>53002</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Praha 2</city>
        <zip>12808</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Praha 5</city>
        <zip>15000</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Zlín</city>
        <zip>76275</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Göttingen</city>
        <state>Lower Saxony</state>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pflaz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Budapest</city>
        <zip>1076</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Budapest</city>
        <zip>1106</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Nyíregyháza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Pecs</city>
        <zip>7621</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Visakhapatnam</city>
        <state>Andhra Pradesh</state>
        <zip>530040</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380015</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380016</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560037</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560094</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400050</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Bhubaneswar</city>
        <state>Orissa</state>
        <zip>751024</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Chandigarh</city>
        <state>Punjab</state>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302015</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Madurai</city>
        <state>Tamilnadu</state>
        <zip>625020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Tirunelveli</city>
        <state>Tamilnadu</state>
        <zip>627002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Hyderabad</city>
        <state>Telangana</state>
        <zip>500034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Noida</city>
        <state>Uttar Pradesh</state>
        <zip>201301</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>4578510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Koriyama</city>
        <state>Fukushima</state>
        <zip>9638052</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>0608604</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Mito</city>
        <state>Ibaraki</state>
        <zip>3100845</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Yamato</city>
        <state>Kanagawa</state>
        <zip>2420001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Susono</city>
        <state>Shizuoka</state>
        <zip>4101102</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Kōfu</city>
        <state>Yamanashi</state>
        <zip>4008506</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>8110213</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Fukushima</city>
        <zip>9601295</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Kagoshima</city>
        <zip>8920824</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Kumamoto</city>
        <zip>8600027</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Nagasaki</city>
        <zip>8528501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Osaka National Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>5400006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Saitama</city>
        <zip>3308553</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Jelgava</city>
        <zip>LV-3001</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Riga</city>
        <zip>LV-1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Riga</city>
        <zip>LV-1006</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Łódź</city>
        <state>Lodzkie</state>
        <zip>91134</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Katowice</city>
        <state>Slaskie</state>
        <zip>40594</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Tarnów</city>
        <state>Tarnow</state>
        <zip>33100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Olsztyn</city>
        <state>Warminsko-Mazurskie</state>
        <zip>10424</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Rzeszów</city>
        <zip>35017</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Wałbrzych</city>
        <zip>58309</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Kazan</city>
        <state>Tatarstan Resp.</state>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Moscow</city>
        <zip>119021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630096</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Omsk</city>
        <zip>644042</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Japan</country>
    <country>Latvia</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 9, 2018</study_first_submitted>
  <study_first_submitted_qc>July 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2018</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Macular Edema,</keyword>
  <keyword>BCVA,</keyword>
  <keyword>ETDRS Letters.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

